Item 5.07. Submission of Matters to a Vote of Security Holders.

On February 8, 2023, Dermata Therapeutics, Inc. (the "Company") held a special meeting of stockholders (the "Special Meeting"). The matters voted on at the Special Meeting were: (1) the adoption and approval of an amendment to the Company's Amended and Restated Certificate of Incorporation, as amended (the "Charter"), to effect a reverse stock split of the issued and outstanding shares of the Company's common stock, par value $0.0001 per share (the "Common Stock"), at a specific ratio, ranging from one-for-two (1:2) to one-for-forty (1:40), with the exact ratio to be determined by the Company's board of directors without further approval or authorization of the Company's stockholders (the "Reverse Stock Split Proposal") and (2) the approval of the adjournment of the Special Meeting to the extent there are insufficient votes at the Special Meeting to approve the Reverse Stock Split Proposal (the "Adjournment Proposal").

At the Special Meeting, both of the matters voted on were approved, based upon an aggregate of 12,321,848 shares of Common Stock outstanding as of December 28, 2022, which was the record date for the Special Meeting. The final voting results were as follows:





Proposal No. 1:  The Reverse Stock Split Proposal was approved by a vote of
stockholders as follows:



Votes For      Votes Against       Abstentions
7,622,928         135,481            39,669




Proposal No. 2:  The Adjournment Proposal was approved by a vote of stockholders
as follows:



 Votes For       Votes Against       Abstentions
 7,681,932          87,554             28,592





2

© Edgar Online, source Glimpses